Clinical trials: Anthracyclines
Breast Neoplasm Female, Lymphoma
Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study
Breast cancer is the most common cancer among women worldwide. Similarly, Hodgkin and non- Hodgkin lymphomas make up two of the most prevalent cancers in men and women.
- Conditions
- Breast Neoplasm Female, Lymphoma, Cardiotoxicity, Anthracyclines
- Trial name
- NCT03850171
- Testing
- Exercise Training
- Where
- 4 sites in Switzerland
- Volunteers
- 57 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Heart Failure, Anthracycline-induced Cardiac Toxicity
Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused…
- Conditions
- Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD), Arterial Stiffness
- Trial name
- Alpaca (NCT07245069)
- Testing
- Dapagliflozin 10 mg
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- University Medical Centre Ljubljana
Newly Diagnosed Acute Myeloid Leukemia (AML)
Cardiotoxicity in Newly Diagnosed Acute Myeloid Leukemia Patients
The aim of this study is to evaluate and compare the cardiotoxic effects associated with anthracycline-based induction chemotherapy and those receiving a Venetoclax or HMA regimens after four cycles of chemotherpy in patients…
- Trial name
- AML/HMA (NCT07851012)
- Volunteers
- 146 people
- Sponsor
- Assiut University
Breast Cancer
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer
This is an open-label, mono-center phase I/II study designed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of RAD001 in combination with carboplatin in taxane- and anthracycline-pretreated…
- Trial name
- NCT00930475
- Testing
- RAD001 (Everolimus) in combination with carboplatin
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Charite University, Berlin, Germany
Metastatic Breast Cancer
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.
- Trial name
- NCT01910870
- Testing
- Cisplatin, Metronomic Cyclophosphamide
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Jean Perrin
Metastatic Breast Cancer
Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer
This study is a multicenter, randomized study, open-label, phase III study.The efficacy of irinotecan and capecitabine combination will be superior to capecitabine alone in term of progression free survival in metastatic breast…
- Trial name
- PROCEED (NCT01501669)
- Testing
- Irinotecan, Capecitabine
- Where
- South Korea
- Volunteers
- 222 people
- Sponsor
- National Cancer Center, Korea
Advanced Liposarcoma or Leiomyosarcoma
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).
- Trial name
- NCT01343277
- Testing
- Trabectedin, Dacarbazine
- Where
- 88 sites in United States, Australia and 2 more
- Volunteers
- 579 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer, Cardiotoxicity
Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab
The aim of the study is to analyze the protective impact on the cardiac damage of beta blockers and ACE inhibitors for breast cancer patients treated with anthracyclines-based chemotherapy with or without trastuzumab.
- Trial name
- SAFE (NCT02236806)
- Testing
- Bisoprolol, Ramipril
- Where
- Italy
- Volunteers
- 262 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Metastatic Breast Cancer
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
To provide extended access to Ixabepilone therapy to subjects with metastatic breast cancer who have completed the previous Phase II study (CA163-107)
- Trial name
- NCT01027208
- Testing
- Ixabepilone
- Where
- 14 sites in Japan
- Volunteers
- 20 people
- Sponsor
- R-Pharm
Breast Cancer
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
The purpose of this study is to evaluate the efficacy and safety of E7389 in Patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine as prior therapy, and who…
- Trial name
- NCT00246090
- Testing
- E7389
- Where
- 65 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Eisai Inc.
Cardiotoxicity, Cardiac Rehabilitation
Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity
This project aims to determine whether a comprehensive cardiac rehabilitation program including supervised exercise training is able to prevent cardiotoxicity during treatment with anthracyclines and / or anti-HER-2 antibodies in…
- Trial name
- ONCORE (NCT03964142)
- Testing
- Cardiac rehabilitation
- Where
- Spain
- Volunteers
- 122 people
- Sponsor
- Hospital Clinico Universitario de Santiago
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
This 3 arm study will assess the tolerability, safety and efficacy of 3 neoadjuvant treatment regimens in participants with locally advanced, inflammatory or early stage human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00976989
- Testing
- Pertuzumab, Trastuzumab, FEC
- Where
- 55 sites in Bosnia and Herzegovina, Brazil and 18 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Hodgkin Lymphoma in Remission, Leukemia in Remission
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment.
- Conditions
- Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma
- Trial name
- NCT01790152
- Testing
- Assessment of Therapy Complications, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 79 sites in United States, Australia and 2 more
- Volunteers
- 420 people
- Sponsor
- Children's Oncology Group
Advanced Solid Tumors - Phase 1 Population
Safety Study of GPX-150 in Patients With Solid Tumors
This is a Phase 1 safety and dose escalation study to define the maximum tolerated dose (MTD) and identify the dose limiting toxicities (DLT) following IV administration of GPX-150 once every 3 weeks.
- Trial name
- NCT00710125
- Testing
- GPX-150 for Injection
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Gem Pharmaceuticals
Breast Cancer
Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00470249
- Testing
- Carboplatin, Gemcitabine Hydrochloride
- Where
- 3 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- University of Southampton
Metastatic Breast Cancer
Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
This is a single-center, open, randomized, controlled phase 2 clinical trial designed to compare low-dose-bevacizumab and pemetrexed with TPC in metastatic HER2-negative breast cancer patients after failure of taxanes and…
- Trial name
- NCT02829008
- Testing
- low-dose-bevacizumab/pemetrexed, Treatment of physician's choice
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese Academy of Medical Sciences
Lymphoma, Heart Failure, Congestive
Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)
Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function…
- Trial name
- NCT00195897
- Where
- 2 sites in France
- Volunteers
- 6 people
- Sponsor
- Centre Henri Becquerel
Cardiotoxicity, Childhood Cancer
Prediction of Delayed Toxic Cardiomyopathy in Children
Longitudinal analysis of myocardial function using "Speckle Tracking Echocardiography" STE analysis and prediction of delayed toxic induced cardiomyopathy in young patients who received anthracycline therapy in childhood.
- Trial name
- SpeckleAnthra2 (NCT05781672)
- Testing
- cardiac ultrasound with speckle tracking analysis
- Where
- France
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Breast Cancer
Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00066547
- Testing
- monoclonal antibody HuHMFG1
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Magnetic Resonance Imaging (MRI) of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Chemotherapy
We will use magnetic resonance imaging (MRI) to investigate tumor changes in women with breast cancer who are receiving anthracycline-based systemic chemotherapy.
- Trial name
- NCT01045044
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kettering Health Network